Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
Overview
- Phase
- Not Applicable
- Intervention
- Anlotinib Hydrochloride
- Conditions
- Lung Neoplasms
- Sponsor
- First People's Hospital of Hangzhou
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- PFS
- Last Updated
- 6 years ago
Overview
Brief Summary
Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world.
Subjects of the study: advanced Lung cancer.
Methods of the study:
This is a real world, prospective, Non-Interventional, Follow-up registration study.
Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle.
End point:
Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients ≥18 years of age, man or woman, who had to provide written informed consent prior to enrollment.
- •Patients who had to have histologically and/or cytologically confirmed NSCLC that failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will obtain benefit from antiangiogenic therapy after investigator's assessment.
- •Eastern Cooperative Oncology Group performance status of 0-2.
Exclusion Criteria
- •Contraindication of anlotinib.
- •Pregnant or lactating women.
- •Other patients who can't enroll after investigator's assessment.
Arms & Interventions
experiment
The patients whose treatment strategy containing anlotinib.
Intervention: Anlotinib Hydrochloride
Outcomes
Primary Outcomes
PFS
Time Frame: 1 year
progression-free survival
Secondary Outcomes
- DCR(1 year)
- OS(1 year)
- ORR(1 year)